ArticleDiscover oncology2025
Prediction of prognostic biomarkers for hepatocellular carcinoma and immune microenvironment infiltration based on single-cell sequencing and RNA-Seq integration.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveEarly diagnosis and prognostic evaluation of hepatocellular carcinoma (HCC) remain significant challenges in clinical management. This study aims to identify prognostic biomarkers in HCC and to explore their implications in immune microenvironment infiltration.
methodsIn this study, we constructed a single-cell transcriptomic atlas of HCC, focusing on the expression profiles of T cell-related genes. Analytical approaches included cell-cell communication analysis and pseudotime trajectory analysis. To further predict and validate T cell-associated prognostic genes, we integrated transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Patients were stratified into high- and low-risk groups based on a prognostic model derived from these biomarkers. Immune infiltration levels in the tumor microenvironment were then evaluated across risk groups.
resultsA total of eight primary tumor samples and seven normal tissue samples were included as raw data in this study. Following stringent quality control and filtering, 53,477 cells were retained for downstream analysis. From these, we isolated 12,333 T cells, which were subjected to further clustering and annotation. The T cell subpopulations identified included 6314 natural killer T cells (NK T cells), 5199 effector memory CD4
conclusionThis study identified and validated prognostic biomarkers in HCC that effectively predict patient survival rates and immune infiltration characteristics. These findings provide a potential foundation for precision medicine strategies in HCC, offering novel insights into the tumor-immune microenvironment and its clinical implications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.